Drugs / Autologous hMSCs
Autologous hMSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02503280 | Mar 2025 → Mar 2030 | left ventricular failure, myocardial infarction | Joshua M Hare | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01392625 Comparator | May 2011 → Aug 2016 | dilated cardiomyopathy | Joshua M Hare | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous hMSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02503280 ↗ |
| Known as | Auto-hMSCs | “Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 X...” NCT01392625 ↗ |
| Known as | auto-human mesenchymal stem cells (hMSC) | “group 1 (n = 18 auto-human mesenchymal stem cells (hMSC))” PMID 25354998 ↗ Oct 2014 |
| Known as | Autologous Human Mesenchymal Stem Cells (hMSCs) | “Autologous Human Mesenchymal Stem Cells (hMSCs)” NCT02503280 ↗ |
| Route | Other | “The injections will be administered transendocardially during cardiac catheterization” NCT01392625 ↗ |